- Home
- SITC vs AVDL Comparison
SITC vs AVDL Comparison
Compare SITC & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- AVDL
- Stock Information
- Founded
- SITC 1965
- AVDL 2015
- Country
- SITC United States
- AVDL Ireland
- Employees
- SITC N/A
- AVDL N/A
- Industry
- SITC Real Estate Investment Trusts
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- AVDL Health Care
- Exchange
- SITC Nasdaq
- AVDL Nasdaq
- Market Cap
- SITC 786.5M
- AVDL 867.3M
- IPO Year
- SITC 1993
- AVDL 1996
- Fundamental
- Price
- SITC $14.61
- AVDL $8.41
- Analyst Decision
- SITC Hold
- AVDL Strong Buy
- Analyst Count
- SITC 9
- AVDL 7
- Target Price
- SITC $38.78
- AVDL $18.86
- AVG Volume (30 Days)
- SITC 683.6K
- AVDL 1.3M
- Earning Date
- SITC 02-27-2025
- AVDL 03-03-2025
- Dividend Yield
- SITC 7.15%
- AVDL N/A
- EPS Growth
- SITC 757.51
- AVDL N/A
- EPS
- SITC 13.71
- AVDL N/A
- Revenue
- SITC $451,683,000.00
- AVDL $138,160,000.00
- Revenue This Year
- SITC N/A
- AVDL $515.49
- Revenue Next Year
- SITC N/A
- AVDL $48.85
- P/E Ratio
- SITC $1.06
- AVDL N/A
- Revenue Growth
- SITC N/A
- AVDL 1523.50
- 52 Week Low
- SITC $14.47
- AVDL $7.39
- 52 Week High
- SITC $64.44
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- SITC 40.76
- AVDL 45.85
- Support Level
- SITC $14.53
- AVDL $8.27
- Resistance Level
- SITC $14.84
- AVDL $9.34
- Average True Range (ATR)
- SITC 0.35
- AVDL 0.44
- MACD
- SITC -0.02
- AVDL 0.09
- Stochastic Oscillator
- SITC 17.18
- AVDL 43.29
About SITC SITE Centers Corp.
SITE Centers Corp is a United States-based self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.